9342-8530 Quebec Inc DGCRF

RE: RE: RE: Question à Ready2Go

[ready2go1]

Thats why I would like to see the share price make a move in the near term. It would give Diagnocure a chance to finance their game plan with GCC. My feeling has been that we would make a quick move to $3.00 that would allow CUR to acquire financing based on PCA3 and the potential of the GCC market. Thought we could settle around the $2.50 range once the deal came out but I have not been right yet. I still see us getting back to $3.00 in the short term but it depends on how Diagnocure is able to manage the news flow. So far they have been unable to keep investors interested and I am not sure if we can hold at various levels during an upswing. Stock seems to drift down without news and follow through. There has been a number of different activities that have taken place that I would say are worthy of a press release. ($3.00 is not my end point but just a stop on to bigger and better things once PCA3 news starts flowing here in the U.S.; >$10.00 is not out of the question. Its a matter of IF we can hold certain levels.
     I'm frustrated and I am sure it is clear by my posts however I am confident in PCA3, and with success of PCA3 brings good things to CUR. We need additional coverage and to get this share price moving so we can get listed here in the States. I had a chance to speak with those who were bringing the last canceled deal to the market and they all said the interest was there from the U.S.
(by the way, U.S. labs want PCA3 but GPRO needs to be careful that they are not promoting and marketing the test)